ArticleJournal of the American Medical Directors Association2021
Are Nursing Home Residents With Dementia Appropriately Treated for Fracture Prevention?
Article in Journal of the American Medical Directors Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Time to reframe osteoporosis: a position statement to characterize the osteoporosis care gap.JBMR plus · 2026Review
- Equipping pharmacists to improve osteoporosis management for aged care residents: a pilot study.Journal of pharmaceutical policy and practice · 2026Article
- Screening for Osteoporosis in Nonagenarians: A Scoping Review.Journal of the American Geriatrics Society · 2025Article
- Multiple large language models versus clinical guidelines for postmenopausal osteoporosis: a comparative study of ChatGPT-3.5, ChatGPT-4.0, ChatGPT-4o, Google Gemini, Google Gemini Advanced, and Microsoft Copilot.Archives of osteoporosis · 2025Article
- Disparities in the Diagnosis and Treatment of Osteoporosis in Persons with Cognitive Impairment and Dementia.Current osteoporosis reports · 2025Review
- How Should Clinicians Discuss Deprescribing with Caregivers of Older Adults Living with Dementia? A Qualitative Study.Drugs & aging · 2025Article
- Osteoporosis management in Australian aged care facilities: a mixed method study.Archives of osteoporosis · 2024Article
- Deprescribing bisphosphonates for older adults with dementia: perspectives of caregivers.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024Article
- Diagnostic Value of Hounsfield Units for Osteoporotic Thoracolumbar Vertebral Non-Compression Fractures in Elderly Patients with Low-Energy Injuries.International journal of general medicine · 2024Article
- Prescriber Perspectives and Experiences with Deprescribing Versus Continuing Bisphosphonates in Older Nursing Home Residents with Dementia.Journal of general internal medicine · 2023Article
- Anabolic and Antiresorptive Osteoporosis Treatment: Trends, Costs, and Sequence in a Commercially Insured Population, 2003-2021.JBMR plus · 2023Article
- Nursing Home PRevention of Injury in DEmentia (NH PRIDE): A pilot study of a remote injury prevention service for NH residents.Journal of the American Geriatrics Society · 2023Article
- Treatment rates and healthcare costs of patients with fragility fracture by site of care: a real-world data analysis.Archives of osteoporosis · 2023Article
- Controversies in Osteoporosis Treatment of Nursing Home Residents.Journal of the American Medical Directors Association · 2022Review
- Improving shared decision-making for osteoporosis pharmacologic therapy in nursing homes: a qualitative analysis.Archives of osteoporosis · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Clinicians struggle with whether to prescribe osteoporosis medications for fracture prevention for older nursing home (NH) residents with dementia, given the lack of evidence in this population. To better understand real-world clinical practice, we conducted a retrospective cohort study examining patterns of fracture prevention medication use for older NH residents with dementia and high fracture risk. Data sources included 2015-16 Medicare claims, Part D prescriptions, and Minimum Data Set (MDS) assessments. Among NH residents aged 65+ with dementia and prior fracture or high fracture risk based on the MDS FRAiL (Fracture Risk Assessment in Long-term care), we assessed medications for fracture prevention using prescription data from 1 year prior through 90 days after the first MDS assessment. Multivariable logistic regression was used to evaluate factors associated with receiving treatment. Most of the sample (n = 72,639) was >80 years (78%), female (82%), and white (88%); 63% had moderate/severe dementia and 60% had an osteoporosis diagnosis. Only 11.6% received fracture prevention medications. In adjusted analyses, treated residents were more likely to be female, Hispanic or other non-black minority, <90 years old, and newly admitted to the NH. Other associated factors included osteoporosis diagnosis, walker or wheelchair use, bone disorders (eg, Paget disease), >5 medications, steroid or proton pump inhibitor use, and regions outside of the Northeast. Resident characteristics suggestive of comorbidity burden and worsening dementia were associated with reduced likelihood of treatment. Low use of fracture prevention medications for NH residents with dementia may reflect an attempt by prescribers reconcile medication use with changing goals of care, or inappropriate underuse in patients who still have high fracture risk. Additional research is needed to help clinicians better evaluate when to use these medications in this heterogeneous and vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.